# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gwen Ifill (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML032-SYN-TD
- Date: 2016-02-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorna Achebe-Price, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review three weeks after surgical staging, on the first treatment day. **S**

## History of present illness

Ms. Ifill returns three weeks after robotic-assisted hysterectomy with removal of both tubes and ovaries, sentinel node mapping and removal of the enlarged para-aortic node. She went home the next morning, needed acetaminophen for about a week and nothing since, and has had no bleeding, fever, leg swelling or bladder trouble. She went back to work last week. The final pathology and molecular results are back, and the multidisciplinary tumor board reviewed them with Dr. Delacroix. She saw the genetic counselor this morning. She came today for her first cycle of dostarlimab with carboplatin and paclitaxel. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Operation | Minimally invasive; home the next day; port sites healed |
| Pathology | Endometrioid adenocarcinoma, grade 2, 65% myometrial invasion; right pelvic sentinel node and one para-aortic node involved |
| Stage and molecular class | FIGO 2013 stage IIIC2ii; POLE wild-type, MMRd, p53 wild-type |
| Lynch syndrome screen | MLH1 promoter hypermethylated: acquired, not inherited |
| Today | Cycle 1 of dostarlimab, carboplatin and paclitaxel |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; weight 72.6 kg |
| Genitourinary | Negative | No vaginal bleeding or discharge; no urinary symptoms |
| Gastrointestinal | Negative | No nausea, diarrhea or abdominal pain |
| Neurological | Negative | No tingling or numbness in the hands or feet |
| Cardiovascular | Negative | No calf pain or leg swelling |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Mood steady; PHQ-9 5; no thoughts of self-harm |

7 systems reviewed. **S**

## Current medications

- Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cycles **S**
- Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles **S**
- Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 72.6 kg; BMI 26.7 kg/m². All vital signs are synthetic.

Hemoglobin: 11.6 g/dL (low); White cell count: 6.4 10*3/uL; Absolute neutrophil count: 3.9 10*3/uL; Platelets: 301 10*3/uL; Creatinine: 0.78 mg/dL; eGFR (CKD-EPI 2011): 87 mL/min/1.73 m²; Glucose: 92 mg/dL; ALT: 18 U/L; AST: 20 U/L; Total bilirubin: 0.4 mg/dL; Albumin: 4 g/dL; Magnesium: 2 mg/dL; TSH: 1.9 mIU/L; Free T4: 1.2 ng/dL; PHQ-9: 5. All results are synthetic.

## Change since baseline

- Hemoglobin: 11.8 g/dL (low) at baseline, 11.6 g/dL (low) at this visit **S**
- White cell count: 6.2 10*3/uL at baseline, 6.4 10*3/uL at this visit **S**
- Platelets: 268 10*3/uL at baseline, 301 10*3/uL at this visit **S**
- Creatinine: 0.82 mg/dL at baseline, 0.78 mg/dL at this visit **S**
- eGFR (CKD-EPI 2011): 82 mL/min/1.73 m² at baseline, 87 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 92 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 124/78, pulse 80; weight 72.6 kg |
| Abdomen | Port-site incisions healed without redness or hernia; soft, non-tender |
| Extremities | No leg or genital swelling; calf circumferences equal (baseline for lymphedema) |
| Neurological | Light touch, pinprick and vibration normal in the hands and feet; ankle reflexes present (baseline before paclitaxel) |
| Skin | No rash (baseline before a checkpoint inhibitor) |
| Psychiatric | Focused and well informed; asks detailed questions |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Endometrioid endometrial cancer, FIGO 2013 stage IIIC2ii, molecular class MMRd** (C54.1). Surgery confirmed nodal spread to the pelvis and the para-aortic region, stage IIIC2ii; the molecular class does not change the stage at stage III but chooses the treatment. For mismatch repair deficient advanced disease, adding a PD-1 inhibitor to carboplatin and paclitaxel greatly lowers the risk of progression, so the tumor board recommends dostarlimab with chemotherapy for six cycles, then dostarlimab alone. Radiation is not planned now and will be reconsidered only if the end-of-treatment CT shows residual nodal disease. Hepatitis B, hepatitis C and HIV tests were negative. Counts, kidney and liver function, magnesium, TSH and free T4 allow full-dose treatment: creatinine 0.78 mg/dL, estimated creatinine clearance about 90 mL/min. **S**
   - Cycle 1 today: dostarlimab 500 mg, then carboplatin AUC 5 (575 mg) and paclitaxel 175 mg/m2 (320 mg), every 21 days for six cycles.
   - Fosaprepitant, palonosetron and dexamethasone before each cycle; ondansetron at home as needed.
   - Temperature twice a day for a week after each cycle; call at once for 38.0 °C or more.
   - Report diarrhea, rash, cough, breathlessness or unusual tiredness at once: possible immune-related effects.
2. **Pelvic and para-aortic nodal metastases** (C77.8). Both enlarged nodes removed; no other node involved. Lymphedema risk is low after sentinel mapping but not zero after para-aortic node removal. **S**
   - Lymphedema check at each visit; report leg or genital swelling.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Surgical pathology, stage and molecular class | After surgery | Up to date | FIGO 2013 stage IIIC2ii; POLE wild-type, MMRd, p53 wild-type; estrogen receptor positive |
| Laboratory | MLH1 promoter methylation | Reflex when MLH1 is lost | Up to date | Hypermethylated: the mismatch repair loss is acquired in the tumor |
| Referral | Genetic counseling | When the tumor screen is abnormal | Completed today | Seen this morning; the result was explained |
| Laboratory | Germline testing for Lynch syndrome and cascade testing of relatives | If MMR loss is not explained by MLH1 methylation, or with a strong family history | Not indicated | MLH1 loss is explained by promoter methylation; she knows that a new family history of colorectal or endometrial cancer at a young age would be a reason to revisit this |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer treatment | Up to date | All negative; no antiviral prophylaxis needed |
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 11.6 g/dL, white cells 6.4, neutrophils 3.9, platelets 301 |
| Laboratory | Creatinine and estimated kidney function (carboplatin dose) | Before each cycle | Completed today | Creatinine 0.78 mg/dL, eGFR 87; carboplatin 575 mg for AUC 5 |
| Laboratory | Liver tests (paclitaxel and checkpoint inhibitor) | Baseline and before each checkpoint inhibitor dose | Completed today | ALT 18, AST 20 U/L, bilirubin 0.4 mg/dL, albumin 4.0 g/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 2.0 mg/dL |
| Laboratory | TSH and free T4 (immune-related thyroid disease) | Baseline and before each checkpoint inhibitor dose | Completed today | TSH 1.9 mIU/L, free T4 1.2 ng/dL (baseline) |
| Laboratory | Glucose (immune-related diabetes) | Baseline and before each checkpoint inhibitor dose | Completed today | 92 mg/dL (baseline) |
| Laboratory | Morning cortisol (immune-related adrenal and pituitary disease) | Baseline and before each checkpoint inhibitor dose | Deferred | Not drawn: she arrived after the morning window, when a cortisol cannot be read. To be drawn before 9 a.m. before cycle 2 in the infusion center. No symptom of adrenal insufficiency |
| Examination | Peripheral neuropathy: symptoms and examination | Baseline and before each taxane cycle | Completed today | Baseline normal before the first paclitaxel dose |
| Examination | Lymphedema | Each visit after lymph node surgery | Completed today | No swelling; baseline calf measurements recorded |
| Medication safety | Nausea and vomiting control | Each cycle | Completed today | Three-drug preventive regimen for carboplatin (an NK1 antagonist, a 5-HT3 antagonist and dexamethasone); ondansetron at home |
| Medication safety | Paclitaxel infusion reaction prevention | Each paclitaxel dose | Completed today | Dexamethasone, diphenhydramine and famotidine before the infusion; observation in the first hour |
| Medication safety | Immune-related adverse event teaching | Before the first checkpoint inhibitor dose and each visit | Completed today | Wallet card and written list of symptoms to report the same day |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 5; no thoughts of self-harm |

## Goal progress

- Endometrial tissue diagnosis and ultrasound within one week, and a gynecologic oncology plan within three weeks of presentation. Outcome by 2016-01-20: Biopsy at the first visit, ultrasound in two days, result in four days, CT in eight, consultation at two weeks. **S**
- Surgical staging within four weeks of diagnosis. Outcome by 2016-02-24: Minimally invasive hysterectomy with sentinel node mapping and para-aortic node removal two weeks after the consultation. **S**
- Six cycles of dostarlimab with carboplatin and paclitaxel every three weeks without a delay of more than one week. In progress; target 2016-06-30. **S**
- Lynch syndrome tumor screening completed and explained before treatment starts. Outcome by 2016-02-24: MLH1 promoter hypermethylation found: acquired, not inherited; genetic counseling done. **S**
- Immune-related adverse events found early: TSH, liver tests, glucose and cortisol checked on schedule. In progress; target 2016-06-30. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses. In progress; target 2016-06-30. **S**

## Medication changes

- Started: Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cycles **S**
- Started: Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles **S**
- Started: Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine **S**
- Started: Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026), National Comprehensive Cancer Network
- Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394 (PMID 37337978) (2023), International Federation of Gynecology and Obstetrics
- Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023), New England Journal of Medicine
- Eskander RN, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer (NRG-GY018). N Engl J Med 2023;388(23):2159-2170 (PMID 36972022) (2023), New England Journal of Medicine
- JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (GlaxoSmithKline label)
- Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026), Society of Gynecologic Oncology
- ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014;124(5):1042-1054 (PMID 25437740) (2014), American College of Obstetricians and Gynecologists
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020), American Society of Clinical Oncology
- Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020), American Society of Clinical Oncology
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Cycles every 21 days in the infusion center, with blood counts, chemistry, TSH and a morning cortisol before cycle 2. Primary care and gynecologic oncology review at cycle 4. Call at once for a temperature of 38.0 °C or more, diarrhea, rash, cough or breathlessness. **S**
- Next scheduled visit 2016-04-28: midpoint of combination treatment: blood counts, immune-related adverse event checks, neuropathy, and mood. **S**
